Bayer wants to build a base for pharmaceutical chemical raw materials
2025-10-02 06:05:12
It has been reported that the Bayer Group is planning to establish a pharmaceutical chemical raw material base in Chongqing. So far, the company has already conducted two rounds of market research in the region, showing its serious interest in the local industry and potential for growth.
Recently, Bayer set up an office in Chongqing and is currently in active negotiations with the Chongqing Changshou Chemical Industrial Park regarding investment opportunities. The initial plan involves launching a chemical production project within the park, aiming to supply affordable raw materials for Bayer’s pharmaceutical operations. Given that the Changshou Industrial Park mainly produces natural gas-based methanol, acetic acid, acetylene, chlor-alkali products, and specialty chemicals, Bayer could source key materials locally, significantly cutting down on operational costs.
Moreover, Bayer holds a large portfolio of non-patented drugs, and there is speculation that some of these may be outsourced to a pharmaceutical manufacturer in Chongqing for production. This move could further strengthen Bayer’s presence in the region and support its long-term business strategy.
According to historical data, Bayer had already authorized Tong Junge to exclusively distribute the new lipid-lowering drug “Bai Si Ting†in Sichuan and Chongqing as early as 2001. This prior collaboration highlights Bayer's longstanding interest in the Chinese market and sets a foundation for future partnerships.
With the growing demand for healthcare products and the strategic advantages of Chongqing’s industrial infrastructure, this potential expansion could mark a significant step forward for Bayer in the region.